You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Sun Pharm Inds Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for SUN PHARM INDS, and when can generic versions of SUN PHARM INDS drugs launch?

SUN PHARM INDS has two hundred and twenty-five approved drugs.

There are three US patents protecting SUN PHARM INDS drugs. There are eleven tentative approvals on SUN PHARM INDS drugs.

There are five patent family members on SUN PHARM INDS drugs in three countries and two hundred and nineteen supplementary protection certificates in sixteen countries.

Summary for Sun Pharm Inds
International Patents:5
US Patents:3
Tradenames:167
Ingredients:158
NDAs:225

Drugs and US Patents for Sun Pharm Inds

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Ltd QUINAPRIL HYDROCHLORIDE quinapril hydrochloride TABLET;ORAL 090800-004 Jun 18, 2009 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Sun Pharm Inds Inc TICLOPIDINE HYDROCHLORIDE ticlopidine hydrochloride TABLET;ORAL 075526-001 Sep 26, 2002 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Sun Pharm Inds Ltd AMOXICILLIN amoxicillin FOR SUSPENSION;ORAL 065113-002 Nov 29, 2002 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Sun Pharm Inds Ltd RISPERIDONE risperidone TABLET, ORALLY DISINTEGRATING;ORAL 077542-002 Aug 6, 2010 AB RX No No ⤷  Try a Trial ⤷  Try a Trial
Sun Pharm Inds Ltd DOXYCYCLINE doxycycline CAPSULE;ORAL 065053-002 Nov 22, 2000 AB RX No Yes ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Sun Pharm Inds

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-001 May 25, 2012 8,952,064 ⤷  Try a Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-001 May 25, 2012 9,078,925 ⤷  Try a Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-003 May 25, 2012 8,952,064 ⤷  Try a Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-001 May 25, 2012 9,089,534 ⤷  Try a Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-003 May 25, 2012 9,078,925 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SUN PHARM INDS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 35 mg ➤ Subscribe 2015-11-25
➤ Subscribe Capsules 30 mg and 40 mg ➤ Subscribe 2012-12-31
➤ Subscribe Capsules 20 mg ➤ Subscribe 2013-06-19
➤ Subscribe Capsules 25 mg ➤ Subscribe 2016-05-16
➤ Subscribe Capsules 20 mg ➤ Subscribe 2013-01-07

International Patents for Sun Pharm Inds Drugs

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2017042835 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2023175542 ⤷  Try a Trial
European Patent Office 3346996 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2023281441 ⤷  Try a Trial
Japan 2018530535 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Sun Pharm Inds Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0454436 SPC/GB96/058 United Kingdom ⤷  Try a Trial PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
1507558 12C0033 France ⤷  Try a Trial PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: CH - 6167801 20110705
0152897 2001C/013 Belgium ⤷  Try a Trial PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
0296560 2/1998 Austria ⤷  Try a Trial PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214
3225249 CA 2019 00023 Denmark ⤷  Try a Trial PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.